Alzheimer’s disease partnership set to continue with clinical trial
Cryoport, Inc. (CA, USA) will continue to assist Stemedica (CA, USA) in developing stem cell-based therapies for Alzheimer’s disease by delivering for their Phase II clinical trial of a single intravenous dose of allogeneic human mesenchymal stem cells.
Cryoport, Inc. (CA, USA) has announced that it has expanded its agreement with Stemedica Cell Technologies, Inc. (CA, USA) to support a Phase II clinical trial evaluating the safety, tolerability and efficacy of stem cell therapy for Alzheimer’s disease (AD).
Cryoport is a provider of cold chain logistics solutions, facilitating the safe transportation of regenerative medicines to clinical research institutions and accredited hospitals worldwide. Cryoport’s partnership with Stemedica, major manufacturers of ischemic tolerant allogenic stem cells, began in 2015 and has led to the delivery of these human stem cells to research centers in Georgia and California (USA).
Stemedica recently demonstrated that intravenous administration of allogenic mesenchymal stem cells to animal AD models resulted in a reduction and delay in amyloid plaque formation, a pathophysiological hallmark of the debilitating neurodegenerative disease. This has prompted the initiation of a Phase II trial enrolling approximately 40 AD patients with mild—moderate dementia to assess the safety, tolerability and preliminary efficacy of a single intravenous dose of allogeneic human mesenchymal stem cells.
“Using Cryoport’s validated cold chain solutions to maintain the integrity of our product line and ensure reliability of delivery to patients across the U.S. is essential to the validity of the trial. Having worked with the team at Cryoport previously, we have no doubt that they are the right partners to support this trial,” stated Nikolai Tankovich, President and Chief Medical Officer of Stemedica.
As the currently available therapeutic options are limited, it is hoped that this work into a stem cell-based treatment will bring the field closer to the development of an effective therapy for the disease.
— Written by Adam Price-Evans
Source: https://prnmedia.prnewswire.com/news-releases/389841431.html?tc=PRNJ_email_html_headlines